Company’s decision to lengthen lipid lowering trial causes controversy

AUTOR(ES)

Lenzer, Jeanne

FONTE

BMJ Publishing Group Ltd.

Documentos Relacionados

• 94% of patients suing Merck over rofecoxib agree to company’s offer
• MD's affidavit decries company's use of prescription data mining
• Cancer expert attacks drug company's funding of research paper
• Prescribing lipid lowering agents.
• Lipid lowering in the young.